X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (319) 319
index medicus (304) 304
simeprevir (252) 252
hepatitis c, chronic - drug therapy (223) 223
hepatitis c (210) 210
male (196) 196
female (187) 187
middle aged (187) 187
antiviral agents - therapeutic use (182) 182
drug therapy, combination (180) 180
ribavirin (178) 178
hepatitis c virus (171) 171
gastroenterology & hepatology (161) 161
sofosbuvir (160) 160
hepacivirus - genetics (154) 154
genotype (148) 148
antiviral agents - administration & dosage (134) 134
aged (133) 133
treatment outcome (128) 128
adult (117) 117
interferon (117) 117
treatment-naive patients (112) 112
hepatitis (98) 98
ribavirin - therapeutic use (96) 96
antiviral agents - adverse effects (95) 95
pegylated interferon (87) 87
hepacivirus - drug effects (84) 84
hepatitis c, chronic - virology (82) 82
hepatitis c - drug therapy (81) 81
antiviral agents (80) 80
telaprevir (80) 80
ribavirin - administration & dosage (78) 78
simeprevir - administration & dosage (77) 77
health aspects (76) 76
simeprevir - therapeutic use (76) 76
virus-infection (70) 70
therapy (68) 68
liver (66) 66
pharmacology & pharmacy (66) 66
plus ribavirin (66) 66
sustained virological response (66) 66
cirrhosis (64) 64
double-blind (64) 64
genotype 1 (63) 63
care and treatment (61) 61
daclatasvir (61) 61
analysis (60) 60
hcv (60) 60
infection (60) 60
liver cirrhosis (60) 60
sofosbuvir - administration & dosage (60) 60
drug therapy (59) 59
infectious diseases (59) 59
biological response modifiers (57) 57
genetic aspects (57) 57
sustained virologic response (56) 56
sofosbuvir - therapeutic use (55) 55
genotype 1 infection (53) 53
ledipasvir (53) 53
sulfonamides - therapeutic use (53) 53
transplantation (53) 53
protease inhibitors (52) 52
liver transplantation (51) 51
simeprevir - adverse effects (50) 50
boceprevir (48) 48
hepatitis c, chronic - complications (48) 48
interferon-alpha - therapeutic use (47) 47
young adult (47) 47
genotype & phenotype (46) 46
gastroenterology and hepatology (44) 44
ribavirin - adverse effects (44) 44
infections (43) 43
interferon-alpha 2a (43) 43
patients (43) 43
retrospective studies (43) 43
heterocyclic compounds, 3-ring - therapeutic use (42) 42
uridine monophosphate - analogs & derivatives (41) 41
proteases (40) 40
recurrence (40) 40
drug administration schedule (38) 38
polyethylene glycols - therapeutic use (38) 38
direct-acting antivirals (37) 37
interferon-alpha - administration & dosage (37) 37
virus diseases (37) 37
abridged index medicus (36) 36
sulfonamides - administration & dosage (36) 36
hepatology (34) 34
protease inhibitor (34) 34
viral load (34) 34
hepacivirus - isolation & purification (32) 32
safety (32) 32
sofosbuvir - adverse effects (32) 32
chronic hepatitis c (31) 31
liver cirrhosis - drug therapy (31) 31
medicine & public health (31) 31
aged, 80 and over (30) 30
chronic hepatitis-c (30) 30
medicine, general & internal (30) 30
polyethylene glycols - administration & dosage (30) 30
recombinant proteins - therapeutic use (30) 30
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Hepatology, ISSN 0168-8278, 2015, Volume 63, Issue 6, pp. 1511 - 1522
Summary Failure to respond to the approved combinations of multiple direct-acting antiviral agents is relatively low in hepatitis C virus treatment... 
Gastroenterology and Hepatology | Daclatasvir | Simeprevir | Treatment | Resistance-associated variants | Ledipasvir | Interferon | Hepatitis C virus | Sofosbuvir | Direct-acting antivirals | Resistanceassociated variants | CHRONIC HCV | CHRONIC HEPATITIS-C | REAL-WORLD | PEGYLATED INTERFERON | DOUBLE-BLIND | GENOTYPE 1 INFECTION | INTERFERON-ALPHA 2A | GASTROENTEROLOGY & HEPATOLOGY | TREATMENT-NAIVE PATIENTS | DACLATASVIR PLUS SOFOSBUVIR | Uridine Monophosphate - administration & dosage | Humans | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Imidazoles - administration & dosage | Carbamates - administration & dosage | Simeprevir - administration & dosage | Uracil - administration & dosage | Benzimidazoles - administration & dosage | Ribavirin - administration & dosage | Treatment Failure | Protease Inhibitors - administration & dosage | Fluorenes - administration & dosage | Drug Therapy, Combination | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Clinical Trials as Topic | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Interferons - administration & dosage | Drug Resistance, Viral - genetics | Anilides - administration & dosage | Sofosbuvir - administration & dosage | Uridine Monophosphate - analogs & derivatives | Macrocyclic Compounds - administration & dosage | Sulfonamides - administration & dosage | Uracil - analogs & derivatives | Development and progression | Protease inhibitors | Drug resistance | Hepatitis C | Proteases
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9941, pp. 403 - 413
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9941, pp. 414 - 426
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2015, Volume 15, Issue 6, pp. 645 - 653
Summary Background Compared with other countries, patients with chronic hepatitis C infection in Japan tend to be older, have more advanced liver disease, and... 
Infectious Disease | INFECTIOUS DISEASES | SIMEPREVIR | INFECTION | CHRONIC HCV | Uridine Monophosphate - administration & dosage | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Drug-Related Side Effects and Adverse Reactions - pathology | Young Adult | Benzimidazoles - administration & dosage | Time Factors | Ribavirin - administration & dosage | Aged, 80 and over | Adult | Female | Fluorenes - administration & dosage | Fluorenes - adverse effects | Uridine Monophosphate - adverse effects | Benzimidazoles - adverse effects | Hepacivirus - isolation & purification | Administration, Oral | Japan | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Drug-Related Side Effects and Adverse Reactions - epidemiology | Asian Continental Ancestry Group | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Aged | Hepacivirus - classification | Sofosbuvir | Care and treatment | Liver | Dosage and administration | Product development | Drug therapy, Combination | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin | Hepatitis | Genotype & phenotype | Liver cancer | Heart attacks | Liver diseases | Human immunodeficiency virus--HIV | Hepatology | Response rates | Interferon | Infections | Drug dosages | Patients
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2015, Volume 62, Issue 5, pp. 1047 - 1055
Background & Aims Simeprevir (SMV) is a once-daily (QD), oral hepatitis C virus (HCV) NS3/4A protease inhibitor approved for treatment of genotype (GT) 1 and... 
Gastroenterology and Hepatology | Simeprevir | Chronic | Response-guided | Efficacy | Safety | TMC435 (10/10) | Hepatitis C virus | Sustained virologic response | Protease inhibitor | Genotype 4 | PLUS RIBAVIRIN | MONOTHERAPY | CHRONIC HEPATITIS-C | PHASE-3 | SUSTAINED VIROLOGICAL RESPONSE | THERAPY | PEGINTERFERON ALPHA-2B | DOUBLE-BLIND | INTERFERON-ALPHA 2A | GASTROENTEROLOGY & HEPATOLOGY | ONCE-DAILY TMC435 | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Polyethylene Glycols - adverse effects | Male | Hepatitis C, Chronic - ethnology | Secondary Prevention | Recombinant Proteins - adverse effects | Simeprevir - adverse effects | Simeprevir - administration & dosage | Ribavirin - administration & dosage | Female | Hepacivirus - drug effects | Drug Administration Schedule | RNA, Viral - analysis | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Drug Therapy, Combination - methods | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Interferon-alpha - adverse effects | Viral Load - drug effects | Viral Load - methods | Genetic aspects | Protease inhibitors | Hepatitis C | Proteases | Health aspects
Journal Article
Hepatology, ISSN 0270-9139, 12/2013, Volume 58, Issue 6, pp. 1918 - 1929
Journal Article
JAMA - Journal of the American Medical Association, ISSN 0098-7484, 05/2015, Volume 313, Issue 17, pp. 1736 - 1744
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2014, Volume 61, Issue 2, pp. 219 - 227
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9973, pp. 1075 - 1086
Journal Article
Gut, ISSN 0017-5749, 06/2015, Volume 64, Issue 6, pp. 948 - 956
Journal Article